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Abstract
Background: Management of patients with gastro-oesophageal reflux disease (GORD) can be assisted by
information predicting the likely response to proton pump inhibitor (PPI) treatment. The aim was to undertake a
study of GORD patients designed to approximate ordinary clinical practice that would identify patient
characteristics predicting symptomatic response to pantoprazole treatment.
Methods: 1888 patients with symptoms of GORD were enrolled in a multicentre, multinational, prospective, open
study of 8 weeks pantoprazole treatment, 40 mg daily. Response was assessed by using the ReQuest™
questionnaire, by the investigator making conventional clinical enquiry and by asking patients about their
satisfaction with symptom control. Factors including pre-treatment oesophagitis, gender, age, body mass index
(BMI), Helicobacter pylori status, anxiety and depression, and concurrent IBS symptoms were examined using logistic
regression to determine if they were related to response, judged from the ReQuest™-GI score.
Results: Poorer treatment responses were associated with non-erosive reflux disease, female gender, lower BMI,
anxiety and concurrent irritable bowel syndrome symptoms before treatment. No association was found with age,
Helicobacter pylori status or oesophagitis grade. Some reflux-related symptoms were still present in 14% of patients
who declared themselves ‘well-satisfied’ with their symptom control.
Conclusions: Some readily identifiable features help to predict symptomatic responses to a PPI and consequently
may help in managing patient expectation. ClinicalTrial.gov identifier: NCT00312806.
Background
Despite the potency of proton pump inhibitors (PPIs) on
gastric acid secretion, it is now evident that they do not
suppress symptoms in patients with gastro-oesophageal
reflux disease (GORD) as completely as was once sup-
posed. Indeed, with the advent of more thorough symp-
tom evaluation, it is now well recognised that both in
the clinical study setting and in ordinary clinical prac-
tice, many GORD patients experience persistence of
troublesome reflux symptoms while taking PPI therapy
[1-3]. Thus, physicians prescribing a PPI for GORD
have an obligation to assess the patient’s symptoms at
an appropriate time after starting treatment and to do
so without any preconceived belief that the PPIs are
invariably successful.
Patients with classical gastro-oesophageal reflux symp-
toms often experience other troublesome symptoms,
such as sleep disturbance, and gastro-intestinal (GI)
symptoms reflective of irritable bowel syndrome (IBS)
[4-7]. The overall symptom burden results from the
summation of all these symptoms and therapeutic stu-
dies that adopt a narrow focus on the classic symptoms,
such as heartburn, risk failing to relate to the more
complex symptom burden that is the patient’se x p e r i -
ence. Partly for this reason, systematic questionnaires
(such as ReQuest™) have been developed to quantify
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related[8,9].
To investigate issues of practical concern to physicians
managing GORD patients in an ordinary practice set-
ting, particularly to address a question that physicians
often ask themselves when initiating PPI treatment for
GORD, namely ‘will this patient respond well or poorly
to treatment?’,w eh a v ee x a m i n e df e a t u r e st h a tm i g h t
help to predict the treatment response.
Methods
Patients and design
This was a multicentre, multinational (167 centres in 21
countries), prospective, open study (ClinicalTrial.gov
identifier: NCT00312806). A pragmatic (as opposed to
an explanatory) design was adopted so that the condi-
tions of the study would resemble the conditions of
ordinary clinical practice so far as possible, thereby opti-
mising the likelihood of the results being relevant to
everyday practice [10,11]. Thus patients were enrolled
on the basis of having symptoms considered by the
investigating physician to justify a diagnosis of GORD,
without further specification of GORD diagnostic cri-
teria. However, participating patients had to be adults
(aged ≥18 years), able to give informed consent and to
be thought likely in the investigator’s judgment to com-
ply with the requirements of the study, particularly com-
pletion of the questionnaires.
Patients with symptoms or evidence of complicated
GORD, with previous upper GI surgery or who had
received Helicobacter pylori (H. pylori) eradication treat-
ment in the preceding 4 weeks were excluded, as were
those who had recently taken acid-suppressing medica-
tions, corticosteroids, non-steroidal anti-inflammatory
drugs or prokinetics. These medications together with
sucralfate, misoprostol, bismuth preparations, other sub-
stances with influence on the relief of acid-related symp-
toms, ketoconazole and other drugs showing pH-
dependent absorption were not permitted during the
period of the study. The study was carried out in accor-
dance with the Declaration of Helsinki. Ethics approval
for the study was obtained locally by all participating
investigation sites.
At enrolment of the patient, the investigator enquired
about the presence of symptoms that would be consis-
tent with IBS and answered ‘yes’, ‘no’,o r‘I do not know’
to the question: ‘Is it possible that this patient does not
only suffer from GORD-related symptoms, but also
from symptoms caused by irritable bowel syndrome
(IBS)?’ This is consistent with the pragmatic design of
the study, and is reflective of clinical practice in many
countries where general practitioners may not be famil-
iar with the Rome III criteria and IBS is largely diag-
nosed based on patient history[12,13].
After enrolment, upper GI endoscopy was performed
to categorise patients as having erosive or non-erosive
reflux disease (ERD or NERD) and to grade oesophagi-
tis, if present, according to the Los Angeles classification
[14,15]. Patients were excluded from further participa-
tion in the study if the endoscopy identified an oesopha-
geal stricture, a Schatzki’s ring, an oesophageal
diverticulum, oesophageal varices, or Barrett’so e s o p h a -
gus. H. pylori status was determined by serology, as this
is the method available to most physicians when endo-
scopy is not done[16].
Patients were then required to attend the investiga-
tion centre on three occasions over an 8-week period.
At the first attendance (baseline, Day 0), they were
given their documentation (the ReQuest™,h o s p i t a l
anxiety and depression scale (HADS), ‘treatment satis-
faction sheet’ and GERDyzer™ questionnaire) and
were supplied with their medication (pantoprazole 40
mg) to be commenced the following day and taken
once daily before breakfast throughout the 8-week per-
iod. Consistent with a pragmatic trial design reflecting
real-life clinical practice, pill counts were not con-
ducted. While reasonable attempts are made to encou-
rage compliance with treatment in pragmatic trial
designs, these should not go beyond what is expected
in normal clinical practice[17]. The first ReQuest™,
HADS and GERDyzer™ questionnaires were to be
completed in relation to Day 0 (i.e. the day before
commencing treatment) and ReQuest™ daily there-
after. HADS and GERDyzer™ questionnaires and the
treatment satisfaction sheet were also completed in
relation to the day before each of the subsequent visits
at Week 4 and Week 8, when they were handed in. At
each of these two visits, the investigator questioned
the patient to establish the ‘investigator’s assessment’
of the adequacy of symptom control.
Assessments
ReQuest™
ReQuest™ is a self-administered scale that provides a
comprehensive evaluation of symptoms in patients suf-
fering from GORD[18-20]. Both, a long and a short ver-
sion have been validated in several languages: the short
version was used in this study. ReQuest™ has not been
validated for the assessment of quality of life. Rather, it
assesses seven dimensions of GORD, namely acid com-
plaints, upper abdominal/stomach complaints, lower
abdominal/digestive complaints, nausea, sleep distur-
bances, other complaints, and general well-being. Each
dimension is assessed in respect of intensity and fre-
quency. Intensity is measured by a 100 mm visual analo-
gue scale (VAS) ranging from ‘not at all’ to ‘extremely
severe’, whereas frequency is measured by a 7-point
Likert scale ranging from ‘0’ to ‘more than 10 times per
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on a VAS, ranging from ‘wonderful’ to ‘extremely poor’.
The dimensions of the ReQuest™ can be grouped into
two sub-scales: ReQuest™-GI (gastrointestinal: includes
acid complaints, upper abdominal/stomach complaints,
lower abdominal/digestive complaints, and nausea) and
ReQuest™-WSO (general well-being, sleep disorders,
and other complaints). The ranges of the ReQuest™
and its sub-scores are as follows:
￿ ReQuest™ total score: 0 to 46.28,
￿ ReQuest™-GI: 0 to 30.77,
￿ ReQuest™-WSO: 0 to 15.51.
Patients were considered to have responded to treat-
ment (to be ‘responders’)i ft h e i rR e Q u e s t ™-GI symp-
tom score was below 1.6 on 3 consecutive days. A score
of 1.6 was the 95% upper confidence limit of the scores
found in healthy subjects[21]. Although only the
ReQuest™-GI sub-scale was used to define response to
treatment, both sub-scales and the total score were used
in exploring the potential of ReQuest™ to predict treat-
ment outcome.
HADS
The HADS was used to assess relationships between the
patients’ symptoms and psychological constitution[22].
The HADS is a well established screening measure for
anxiety and depression used in outpatient clinics. It
comprises 14 items and is subdivided in two subscales
with 7 items relating to anxiety and 7 to depression.
The two subscales each range from 0 to 21 and the
total scale from 0 to 42. According to Snaith[23], a
score of 0 to 7 for either subscale can be regarded as
the normal range; a score of 8 to 10 is suggestive of the
presence of the respective state and a score of 11 or
higher indicates the probable presence of a mood
disorder.
Patient satisfaction
At the follow up visits to the investigation site 4 and 8
weeks after commencing treatment, patients handed in
their treatment satisfaction sheet, categorising their
satisfaction with symptom control during the preceding
24 hours as ‘very satisfied’, ‘fairly satisfied’ or ‘not
satisfied’.
Investigator assessment
At the same visits, the investigator made conventional
clinical enquiry about the patient’ss y m p t o m sa n d
assessed them as being ‘well-controlled’, ‘fairly-con-
trolled’ or ‘not controlled’.
Quality of Life assessment: the GERDyzer™ questionnaire
The GERD Analyzer (GERDyzer™) is a health-related
quality of life questionnaire to evaluate the impact of
GORD on the patient’s quality of life[24]. GERDyzer™
assesses 10 dimensions of quality of life (i.e. general
well-being, pain/discomfort, physical health, energy,
daily activities, leisure activities, social life, diet/eating/
drinking habits, mood and sleep). Each dimension is
assessed using a 100 mm VAS ranging from ‘n o ta ta l l ’
to ‘very much’ (except ‘general well-being’:f r o m‘excel-
lent to ‘unbearably bad’): higher GERDyzer™ scores
indicate greater quality of life impairment.
Statistical analysis
The factors investigated as possible influences on
response to treatment were: age, body mass index
(BMI), gender, geographical location, H. pylori status,
symptoms suggesting IBS as well as GORD, presence of
oesophagitis before treatment, the grade of oesophagitis,
if present, and the HADS scores (total and sub-scores).
All factors were described by frequencies and percen-
tages for the subgroups responder and non-responder.
An univariate logistic regression analysis was used to
assess the influence of each of these factors, with the
appropriate response rates after 8 weeks treatment (pro-
portion of patients being responders to treatment) being
the dependent variable and the investigated factors as
independent variables. A p-value of < 0.05 was taken to
indicate significant influence of the independent vari-
able. In addition, a global multivariate analysis was per-
formed to take into account any effects of confounding.
The regression model considered the HADS as total
score and ERD/NERD only by their presence rather
than by oesophagitis grades.
Some reports in the literature indicate that symptom
severity before treatment and/or the symptom response
occurring in the first few days of treatment can predict
the later treatment outcome[25-29]. For this reason,
ReQuest™ total and subscale scores relating to the pre-
treatment day and the first 10 days of treatment were
examined to identify the potential for the scores to
serve as a clinically useful predictor of treatment out-
come (response or non-response) at 8 weeks. For each
of the 11 days, response and non-response prediction
rates for the whole score ranges of the respective
ReQuest™ scores were determined. The premise was
that scores equal to or below a selected level would pre-
dict ‘response’ and those above another selected level
would predict ‘non-response’. Taking scores in increas-
ing steps of 0.01 from 0 to the maximum score on each
of the 11 days, prediction rates for response and non-
response were calculated as:
Number of correctly predicted responses (non - responses)
Number of predicted responses (non - responses)
× 100
For all time points, the highest prediction rates for
response and non-response at the end of 8 weeks treat-
ment were identified. The difference between the corre-
sponding response and non-response prediction levels
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This permitted the range of score values failing to predict
either response or non-response to be as small as possi-
ble. After the determination of the ReQuest™ score,
which fits the above described properties best, a logistic
regression analysis (as specified above) was conducted to
investigate the possible influence of this ReQuest™ score
on the response to treatment. All calculated p-values
were interpreted in an explorative sense [30].
Results
In total, 1928 patients were recruited through 167 inves-
tigational sites (specialist and primary care centres) in
21 countries. The safety population comprised 1901
patients. The intention-to-treat population (ITT) was
1888 patients: their demographic and other data at base-
line are presented in Tables 1 and 2.
Response rates
The overall response rates (i.e., ReQuest™-GI symptom
score below 1.6 on 3 consecutive days) for the ITT
population were 58.9% at Week 4 and 71.2% at Week 8.
Logistic regression analysis data assessing the influence
of various factors independently on response rates fol-
lowing pantoprazole treatment is presented in Table 3.
The presence of ERD, lower baseline HADS scores (total
and sub-scores) and higher BMI were associated with a
response to therapy (all p < 0.0001), as were male gender
(p = 0.0011) and differences in geographic location (p =
0.0052). Concurrent IBS symptoms were associated with
poorer response to treatment (p < 0.0001). In contrast,
pre-treatment H. pylori status, oesophagitis grade and
age showed no statistically significant influence on treat-
ment response (Table 3). Further details of the factors
influencing response are presented below.
The results of the global multivariate regression analy-
sis revealed one difference to the univariate model: for
the factor gender, no significant influence on response
was found. All other factors that were significantly asso-
ciated with treatment response in the univariate analysis
were likewise significant in the multivariate analysis.
ERD vs. NERD; gender
At the end of the 8 weeks of treatment, patients who
had erosive reflux disease (ERD) pre-treatment showed
higher response rates than those with NERD (75.5% vs.
64.5%; Figure 1). Among patients with ERD before treat-
ment, however, no statistically significant differences in
response rates were seen according to grade of oesopha-
gitis. Male patients had a higher response rate than
female patients (74.9% vs. 67.8%; Figure 1).
Geography
In Western Europe, South America and Canada, response
rates were comparable at Week 4 (approximately 60%)
and at Week 8 (approximately 72%). Highest response
Table 1 Demographic data and baseline characteristics
(ITT, n = 1888)
Age [years], mean (SD) 47.0 (14.3)
Height [cm], mean (SD) 167.5 (9.6)
Weight [kg], mean (SD) 74.2 (15.8)
BMI [kg/m
2], mean (SD) 26.4 (4.8)
Gender, n (%) Female 978 (51.8)
Male 910 (48.2)
Ethnic origin, n (%) White 1326 (70.2)
Asian 352 (18.6)
Other 167 (8.8)
Black 43 (2.3)
Patients per continent, n (%) Western Europe 894 (47.4)
South America 352 (18.6)
Asia 326 (17.3)
Canada 124 (6.6)
South Africa 100 (5.3)
Australia 92 (4.9)
Smoker, n (%) Never 1179 (62.4)
Former 360 (19.1)
Current 349 (18.5)
Table 2 Additional baseline data (ITT, n = 1888)
N (%)
H. pylori status Positive 687 (36.4)
Negative 1070 (56.7)
Intermediate 98 (5.2)
Missing 33 (1.7)
Oesophagitis Non-erosive 694 (36.8)
Grade A 680 (36.0)
Grade B 381 (20.2)
Grade C 97 (5.1)
Grade D 23 (1.2)
Missing 13 (0.7)
Table 3 Factors influencing treatment response
Factor Logistic regression p-value
ERD/NERD <0.0001
HADS total score <0.0001
￿ Anxiety sub-score <0.0001
￿ Depression sub-score <0.0001
IBS <0.0001
BMI <0.0001
Gender 0.0011
Geography 0.0052
H. pylori Not significant
Age Not significant
Oesophagitis grade (A-D) Not significant
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Africa (82.5%), lowest response rates in Asia (60.8%) and
Australia (61.7%).
Anxiety and depression
The HADS total score and both sub-scores (Figure 2)
decreased over time for responders as well as for non-
responders. At baseline, both, responders and non-
responders had a mean anxiety sub-score suggestive of the
presence of an anxiety state. Under treatment, the score
fell to normal in the responders (below 7; Figure 2). A fall
was also apparent in non-responders, but their score was
still above normal at Week 8. In contrast, the depression
sub-scores provided no evidence of depression at any time
in either responders or non-responders (all scores were
below 7 at all timepoints; Figure 2). Overall, non-
Figure 1 Response rates after 4 and 8 weeks: presence of oesophagitis and gender. Statistical results are given in Table 3 and in the text.
Figure 2 HADS scores. Statistical results are given in Table 3 and in the text. *Score of ≥11: probable presence of mood disorder. **Score of ≥7
to <11: suggestive for presence of mood disorder (scores <7: normal range).
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than responders at all estimated time points. Higher base-
line HADS scores (total and both sub-scores) were thus
statistically associated with non-response to treatment.
Irritable bowel syndrome
Symptoms suggesting concurrent IBS at the time GORD
treatment was begun were found to be associated with
poorer response rates. The findings at 8 weeks are
shown in Figure 3.
Body Mass Index
BMI was positively associated with response to treatment
(Table 3). Differences were found between responders
and non-responders both at Week 4 (BMI = 26.9 vs. 25.7
respectively) and at Week 8 (BMI = 26.8 vs. 25.7).
Prediction of response using ReQuest™ scores
Table 4 shows the optimum prediction levels and the
corresponding prediction rates for response and non-
response (i.e. the proportion of patients with a score
below/above the respective prediction level who were
classified as responders/non-responders to treatment at
Week 8) using the ReQuest™ total score and sub-
scores. The table shows, for example, that the calculated
time point for the best prediction using ReQuest™-GI
was Day 10. Here, 1043 patients had ReQuest™-GI
scores at or below 1.47. Of these, 914 were responders
at Week 8, giving a prediction rate for response of
87.6%. Of 154 patients with ReQuest™-GI scores above
8.38, 108 patients were non-responders at Week 8.
Thus, the prediction rate for non-response was 69.9%.
The calculated best time point of prediction for the
ReQuest™ total score was also Day 10, whereas it was
Day 4 for ReQuest™-WSO. Prediction rates for
response and non-response were similar for ReQuest™
total score and ReQuest™-GI (response: 87%, non-
response: 70%) but were lower for ReQuest™-WSO.
In addition to identifying the time point for the best
prediction, the capability of ReQuest™ scores at base-
line (the day before treatment commenced) to predict
treatment outcomes at Week 8 was examined and the
results are also given in Table 4. The prediction rates
for response were 79.8% for ReQuest™ total score,
80.9% for ReQuest™-GI, and 80.6% for ReQuest™-
WSO. The prediction rates for non-response were 60.0%
for ReQuest™ total score, 61.3% for ReQuest™-GI, and
73.7% for ReQuest™-WSO. Figure 4 shows these results
for ReQuest™-GI in relation to the numbers of patients
in whom prediction may be made.
Control of Symptoms and Patient Satisfaction
The investigators’ assessments of patient symptom con-
trol and the patients’ own assessments of their satisfac-
tion with symptom control at Week 8 are shown in
Figure 5 in relation to their categorisation as responders
or non-responders. A minority of patients judged by the
investigator to have their symptoms well-controlled
were in fact non-responders according to ReQuest™-GI
(310 out of 1450), which suggests that the investigators
tended to be overoptimistic about the adequacy of
symptom control achieved. Interestingly, there was also
a minority of patients, albeit a smaller proportion, who
were non-responders according to their ReQuest™-GI
questionnaires despite declaring themselves to be very
satisfied by their symptom control (155 of the 1110 who
were ‘very satisfied’). However, only 0.8% of patients
who were responders according to ReQuest™-GI were
‘not satisfied’ with their symptom control.
Quality of Life: the GERDyzer results
The GERDyzer™ scores are shown in Figure 6.
Improvement in quality of life (reduction in score) was
evident during the period of treatment in both respon-
ders and non-responders, though the baseline score was
higher in the non-responding group and the falls in
score during treatment (baseline to Week 4 and baseline
to Week 8) were significantly greater in the responders
(Week 4 and Week 8: p < 0.0001). Thus more complete
symptom control, as assessed by ReQuest™-GI, was
associated with better quality of life.
Adverse events
In the course of the study, 477 patients of the safety set
(25.1%) experienced 784 treatment-emergent adverse
Figure 3 Response rates at 8 weeks according to the presence
or absence of IBS symptoms at baseline. Statistical results are
given in Table 3 and in the text.
Heading et al. BMC Gastroenterology 2011, 11:52
http://www.biomedcentral.com/1471-230X/11/52
Page 6 of 12events. Only 2 of these (0.3%) were assessed as definitely
related to the study medication. Most of the 784 events
were of mild (56.9%) or moderate (37.9%) intensity. No
patient died during the study. Sixteen serious adverse
events were documented in 14 patients (0.7%): 14 were
assessed as unrelated and 2 as unlikely related to the
intake of pantoprazole. The most frequently reported
events using the terminology of the Medical Dictionary
for Regulator Activities (MedDRA) were headache, diar-
rhoea, nausea, abdominal pain, and influenza. Other
events occurred in less than 1% of the patients. Overall,
the treatment was well tolerated.
Discussion
The interpretation of clinical studies undertaken to
investigate the efficacy of therapy is often constrained
by the fact that the typical study setting differs from
conditions in ordinary clinical practice. GORD studies
undertaken on patients with oesophagitis which have
used ‘r e l i e fo fh e a r t b u r n ’ as the principal symptom out-
come fail to take into account two important facts now
widely acknowledged: first,t h a tm a n yG O R Dp a t i e n t s
do not have oesophagitis and second, that the symptom
burden experienced by GORD patients is much more
complex than heartburn alone[31]. In addition, despite
differences in healthcare systems it is now generally
accepted that the use of PPIs to treat GORD is not con-
ditional on first obtaining an upper GI endoscopy. The
diagnosis is usually made and treatment started on the
basis of clinical history, very often in a primary care
setting.
To obtain information relevant to this clinical situa-
tion, our study was therefore undertaken with a prag-
matic rather than explanatory trial design and patients
were enrolled in the trial on the basis of a clinical his-
tory of GORD. In explanatory trials, participating
Table 4 Prediction level and prediction rates for response at Week 8
Prediction level Prediction rate for
Time point of prediction Response
(ReQuest™ score [N*])
Non-response
(ReQuest™ score [N**])
Response (% [N]) Non-response (% [N])
ReQuest™ total Day 10 <3.42 [1046] >13.37 [148] 87.1 [911] 70.3 [104]
ReQuest™-GI Day 10 <1.47 [1043] >8.38 [154] 87.6 [914] 69.9 [108]
ReQuest™-WSO Day 4 <2.24 [1057] >4.89 [220] 82.3 [870] 60.5 [133]
ReQuest™ total Baseline(Day 0) <9.13 [1068] >29.71 [35] 79.8 [852] 60.0 [21]
ReQuest™-GI <5.91 [1047] >21.90 [31] 80.9 [847] 61.3 [19]
ReQuest™-WSO <3.10 [1044] >11.65 [19] 80.6 [841] 73.7 [14]
Data for ITT population without missing values for response at Week 8 (n = 1738)
*Number of patients with ReQuest™ score below the prediction level of response
**Number of patients with ReQuest™ score above the prediction level of non-response
Figure 4 Prediction of response using ReQuest™-GI. N = number of patients.
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defined symptom criteria, perhaps with positive results
from investigations, rather than on the basis of the way
diagnoses are made in everyday clinical practice. The
relevance of findings made in explanatory trials to every-
day clinical practice may therefore be impaired because
the patient population being studied is not the popula-
tion being treated in ordinary practice[10,11]. Classical
explanatory trials of PPI therapy in GORD have mostly
overestimated the success of treatment in comparison
with the therapeutic outcomes achieved in ordinary clin-
ical practice[32].
A diagnosis of GORD made on the basis of the clini-
cal history has specificity of around 65%[33,34], implying
that misdiagnosis is not infrequent and this will cer-
tainly be responsible for some instances of poor treat-
ment responses, sometimes called ‘PPI failure’[35,36].
Our focus in this study was not to identify causes of PPI
failure, but rather to address questions that are often at
t h ef o r e f r o n to fap h y s i c i a n ’s mind when initiating PPI
therapy for GORD. We selected features identifiable at
the time of starting treatment that would possibly have
influence on therapeutic outcome and then prospec-
tively tested whether they did so. These features were:
age, body mass index (BMI), gender, geographical loca-
tion, H. pylori status (determined serologically), symp-
toms suggesting IBS as well as GORD, presence of
oesophagitis before treatment, the grade of oesophagitis,
if present, and anxiety and depression. Response to
treatment was defined in terms of symptom relief,
because in clinical practice it is not usual to perform
endoscopy to assess healing of any pre-treatment oeso-
phagitis unless troublesome symptoms persist on treat-
ment or alarm features appear.
The patient self-administered ReQuest™ question-
naire used in this study is a validated, systematic and
comprehensive assessment of frequency and severity of
symptoms shown to be GORD-related[18-20]. Response
to treatment is defined as a decrease in symptom score
to one equal to or below the score that has been identi-
fied in healthy individuals[21].
Patients with NERD have been found in previous stu-
dies to respond to PPI treatment less well than those
with ERD[37-39]. This is usually attributed to inclusion
of some patients in the NERD group who do not have
reflux disease, notably patients with ‘functional heart-
burn’, who are expected to respond poorly to acid sup-
pression. In line with these findings, our data show a
better response rate in patients with ERD than in
NERD. In addition, our patients with ERD showed no
significant differences in response rates according to
grade of oesophagitis. If NERD patients with ‘true’ reflux
disease were to respond similarly to those with ERD,
these observations suggest a functional heartburn preva-
lence of around 4% among the patients recruited to this
study.
Previously published studies are inconsistent regarding
the existence of a gender difference in response to PPI
treatment[26,39]. Our findings in the univariate analysis
indicate that males show a better response than females.
Of course, NERD is more common in females and so
the lower response rates illustrated in Figure 1 may be
partly explained by confounding. However, as described
Figure 5 Patient and investigator assessments at Week 8.N=
number of patients.
Figure 6 Quality of life (GERDyzer™ scores). Statistical results are
given in Table 3 and in the text.
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from logistic regression and relate to each factor consid-
ered independently.
IBS is known to be more frequent in patients with
GORD than in control populations[40-42] and is also
more prevalent in females[43-45]. In our patients, con-
current IBS symptoms were associated with a lower
response rate to the PPI when compared with patients
without concurrent IBS symptoms. There are uncertain-
ties about the interpretation of this observation, how-
ever. It may be supposed that the inclusion of lower
abdominal complaints in the spectrum of symptoms
assessed by the ReQuest™-GI questionnaire will inevita-
b l yi m p l yah i g h e rr a t eo fs y m p t o m‘non-response’ if
these lower abdominal symptoms are unaffected by acid
suppression. Surprisingly, though, previous studies using
ReQuest™ have found that the lower abdominal symp-
toms in GORD patients do improve during PPI treat-
ment[20,46-48] suggesting that these symptoms are not
independent. Perhaps the mechanisms underlying classi-
cal reflux symptoms and the lower abdominal symptoms
are somehow linked or the symptoms are linked within
the patients’ perceptions of overall symptom burden.
Many physicians would predict that patients with con-
current anxiety or depression would respond poorly to
GORD treatment and previous studies have borne this
out[26,49]. Our data likewise show that a high HADS
score before treatment was associated with a poorer
response, although anxiety seemed to be more relevant
than depression. Nevertheless, the anxiety sub-score fell
to normal in the patients who responded to treatment,
consistent with a contention that GORD symptoms
were causing some of the anxiety while the higher anxi-
ety sub-scores seen in non-responders than responders,
especially at baseline, are consistent with the possibility
that anxiety may itself contribute to the perceived GI
symptom burden. The possibility thus exists of a two
way relationship between anxiety and GORD symptoms.
Our data showing an association between BMI and
response rate was statistically highly significant and this
observation was not expected. Although published data
clearly link obesity and GORD[50-52], and indeed a cor-
relation between BMI and GORD is also evident within
the normal BMI range[53], there has been little investi-
gation of the effect of BMI on responses to antisecretory
treatment[54,55]. However, one recent study found a
positive correlation between BMI and symptom relief
when lansoprazole therapy was given to patients with a
wide range of upper GI symptoms and negative upper
GI endoscopy[56]. The authors suggested their findings
could be explained by an association of higher BMI with
GORD and a good response of acid reflux symptoms to
treatment; this explanation could be relevant to our
findings also.
An aspect of our results worth comment was the fail-
ure to find any link between age or H. pylori status on
response rates. The literature is inconclusive with
respect to H. pylori: Hatlebakk et al.[57] found H. pylori
infection to have no effect on response to treatment
whereas Labenz et al.[58] found greater age and a posi-
tive H. pylori status were both positively associated with
better resolution of heartburn over a 4-week treatment
period. The failure to find a link between H. pylori sta-
tus and response may have resulted from the use of the
serology for H. pylori diagnosis, which does not distin-
guish between cured and active infection[16].
Impaired quality of life is well-established as a conse-
quence of GORD and improves with treatment[59-61].
Our results show that the baseline GERDyzer™ score
was higher (indicating greater quality of life impairment)
in the patients who subsequently responded poorly to
treatment and that these non-responders also showed a
smaller absolute improvement (fall in score) during
treatment.
It is interesting to compare the symptom control deter-
mined by the ReQuest™-GI questionnaire with the
investigators’ assessments of symptom control and with
the patients’ own assessments of satisfaction with symp-
tom control. The biggest disparity, as shown in Figure 5,
was in the proportion of patients judged by the physician
to have been ‘well-controlled’ who nevertheless were
non-responders according to ReQuest™-GI. This sug-
gests physicians tend to overestimate patients’ responses
to treatment, as has been previously reported[62,63]. The
‘satisfaction’ findings are also of interest, however, in that
some 14% of patients who rated themselves to be ‘very
satisfied’ with symptom control were ‘non-responders’
according to ReQuest™-GI. Patients may thus be satis-
fied with symptom control that is less than total, which
raises an issue about whether attainment of a predefined
level of symptom suppression or a ‘very-satisfied’ patient
should be the objective of therapy. It may certainly be
argued that GORD has been adequately treated if the
residual symptoms a patient still has while on treatment
a r ej u d g e db yt h a tp a t i e n tn o tt ob et r o u b l e s o m e .M o r e -
over, in ordinary clinical practice it is to be expected that
ap a t i e n t ’s satisfaction with symptom control will influ-
ence the physician’s assessment: a very satisfied patient
may reasonably lead the doctor to consider that the
GORD symptoms are ‘well-controlled’. Nevertheless, the
discrepancies between these different measures of treat-
ment success illustrate the difficulties of measuring the
occurrence and impact of symptoms and of establishing
unequivocally what the most clinically relevant treatment
goal should be. Of course, the dilemma is well recognised
in other areas of clinical medicine also[64].
Geographical and ethnic differences in the nature, pre-
valence and presentation of GORD are recognised[65]
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to treatment. Unfortunately, it is not clear whether the
geographical variation in responses is a reflection of fun-
damental differences in GORD biology or an artefact of
the study. Minor differences in local systems of patient
recruitment, for example, may have had an effect on
patient outcomes. Consequently, we do not wish to sug-
gest any interpretation of the observed geographical
variation.
Prompted by reports that treatment outcome may be
predicted by symptom severity before or shortly after
commencing treatment [25-29], the potential for the
ReQuest™ questionnaire to predict the response to
treatment was comprehensively evaluated and the
results show that some predictive capability is possible
both in respect of response and non-response (Table 4).
The results that relate to the baseline are especially
interesting in that a prediction of treatment outcome
before the treatment begins could potentially help the
physician in managing patient expectation. However, the
probabilities of correct prediction shown in Figure 4 are
perhaps lower than physicians would wish and the pro-
portion of patients for whom no prediction could be
made was higher. However, using an abbreviated form
of ReQuest™,( R e Q u e s ti nP r a c t i c e ™)[66], scores
obtained from the questionnaire were more accurate
than the physicians’ conventional clinical enquiry in
identifying patients whose symptoms would still be con-
trolled after stepping down from full dose to half dose
PPI[67]. In this context at least, therefore, prediction
based on the systematic assessment of symptom burden
is potentially valuable, being more reliable than ordinary
clinical judgment.
Conclusions
Overall, these results suggest that in the setting of every-
day clinical practice, several readily identifiable features
can help physicians to foresee the likely success of pan-
toprazole treatment in controlling symptoms in GORD
patients and so to manage patient expectations accord-
ingly. While some of the observations, such as the sig-
nificance of NERD rather than ERD and of concurrent
IBS or anxiety are not unexpected, others such as the
apparent influence of BMI and the lack of influence of
oesophagitis severity might be thought contrary to clini-
cal intuition. Of course, misdiagnosis almost certainly
explains some instances of non-response to PPI treat-
ment and the fallibility of symptom-based diagnosis of
GORD is well documented. Pre-treatment identification
of features that predict a poor outcome might therefore
prompt the physician to review his symptom-based diag-
nosis of GORD before prescribing medication and con-
sider whether any diagnostic procedures such as
endoscopy or pH-metry should be undertaken.
Additionally, our results show that although there is a
broad concordance between control of reflux symptoms
and patient satisfaction with treatment, there are some
patients who are very satisfied with their treatment
despite incomplete symptom control. This serves as a
reminder of the subjective nature of symptoms and of
symptom impact and that patient satisfaction deserves
as much consideration as direct symptom assessment
when evaluating treatment success.
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